Charlotte's Web
High-CBD hemp cultivar bred by the Stanley brothers for seizure management.
Growing, buying or possessing cannabis and seeds is legal only in some places. Check the law where you live before acting on this information.
Charlotte's Web is a real high-CBD plant that became famous because of one child's seizure reduction — and that story genuinely helped change cannabis policy. But the *plant* and the *brand* are different things now. Bottles sold under the Charlotte's Web name are formulated extracts, not the original genetics. Clinical evidence for CBD in epilepsy is strong, but it comes from controlled trials of purified CBD (Epidiolex), not this cultivar specifically.
Overview & history
Charlotte's Web is a high-CBD, low-THC cannabis cultivar developed in Colorado by the Stanley brothers in the early 2010s [1]. It was named for Charlotte Figi, a child with Dravet syndrome whose family reported dramatic reductions in seizure frequency after using an oil made from the plant—a story that became widely known through CNN's 2013 documentary Weed with Dr. Sanjay Gupta [1].
Chemically, Charlotte's Web resembles industrial hemp far more than a typical recreational cannabis strain. Independent testing and the company's own descriptions place it at roughly 12–17% CBD and at or below 0.3% THC [1][2]. It produces no meaningful intoxicating effect at normal doses, which is why early growers reportedly called it 'Hippie's Disappointment' [1].
The strain played a significant role in expanding state-level CBD access laws and contributed to the policy environment that led to the FDA's approval of Epidiolex (a purified CBD pharmaceutical) for certain epilepsies [3][4]. It was also central to the political conversation surrounding the 2018 U.S. Farm Bill's legalization of hemp [4].
Cannabinoid profile & chemistry
Charlotte's Web is a chemotype III plant—CBD-dominant with negligible THC Strong evidence[2][3]. Published test results and independent reporting consistently show CBD in the low- to mid-teens by dry weight and THC under the U.S. federal hemp limit of 0.3% [1][2].
Minor cannabinoids reported in the cultivar include CBG, CBC, and trace THCV, though concentrations vary by phenotype and growing conditions Weak / limited. There is no peer-reviewed terpene profile of the original Charlotte's Web cultivar in the published scientific literature; vendor-reported profiles commonly list myrcene, pinene, and caryophyllene as prominent, but these should be treated as batch-specific claims rather than a definitive cultivar fingerprint Weak / limited.
An important distinction: the plant and the product are not the same thing. 'Charlotte's Web' is now also a consumer brand and publicly traded company that sells formulated hemp extracts. The cannabinoid content of bottled products is standardized during formulation, not a direct reflection of the raw flower's chemistry.
Reported effects & clinical evidence
There are no controlled clinical trials of Charlotte's Web the cultivar in humans. What exists instead is (a) the well-documented anecdotal reports and case observations surrounding Charlotte Figi and other families using high-CBD extracts for pediatric epilepsy, and (b) the much larger clinical evidence base for purified pharmaceutical CBD (Epidiolex), which is a different product made by a pharmaceutical company, not a cultivar-specific outcome [3][5].
Users and caregivers commonly report:
- No intoxicating effect Strong evidence—this is reliable because THC content is demonstrably below the threshold for intoxication.
- Subjective calming, reduced anxiety, and improved sleep Anecdote—widespread user report, but not measured in controlled settings specific to this cultivar.
- Reduced seizure frequency in some pediatric epilepsy cases Weak / limited—the strongest signal comes from open-label observational studies of artisanal high-CBD extracts, which are prone to selection bias, reporting bias, and placebo effects [5].
The rigorous clinical evidence that CBD reduces seizure frequency in Dravet syndrome and Lennox–Gastaut syndrome comes from randomized controlled trials of pharmaceutical-grade purified CBD, not Charlotte's Web specifically Strong evidence[3]. Extrapolating those results to any given hemp extract product is reasonable as a general direction but not for dose-specific predictions or guarantees. The Charlotte Figi story is real and catalyzed important policy change; it is not, by itself, clinical evidence that this strain treats epilepsy.
Lineage & genetics
Charlotte's Web's parentage is disputed and incompletely documented Disputed. The Stanley brothers have described the original cultivar as originating from a high-CBD industrial hemp cross they called 'Hippie's Disappointment,' which they then selectively bred and stabilized for CBD content [1]. Beyond that account, no verified, peer-reviewed genetic pedigree exists in the public literature.
Genetic studies of commercial cannabis have repeatedly shown that strain names are unreliable indicators of underlying genetics across different growers and seed sources [6]. Plants sold as 'Charlotte's Web' from different licensed producers are not guaranteed to be genetically identical to the Stanley brothers' original line. Any detailed ancestry chart you encounter on seed-bank or strain-database websites should be treated as folklore unless it cites verifiable breeder documentation.
Growing Charlotte's Web
Charlotte's Web is grown both at large outdoor scale (as a licensed hemp crop) and indoors by smaller operators. Key notes from grower reports and licensed hemp producers:
- Flowering time: approximately 9 weeks indoors under a 12/12 photoperiod; outdoors at temperate North American latitudes, it typically finishes in early to mid-October Weak / limited.
- Plant structure: medium height, moderately branching, consistent with high-CBD hemp phenotypes Weak / limited.
- THC compliance risk: even a CBD-dominant chemotype III plant can drift above the 0.3% THC federal hemp limit if stressed, harvested late, or grown under unfavorable conditions. Licensed hemp growers conduct compliance testing near harvest to confirm THC levels stay within legal bounds [4].
- Growing difficulty: moderate. The plant is not especially finicky, but commercial operators prioritize even canopy development and timely harvest to avoid THC overage.
Publicly available, verified data on indoor yield specific to this cultivar is minimal; figures posted on strain-finder websites are predominantly user-submitted estimates and should not be treated as reliable specifications.
Marketing vs. reality
Several distinctions are worth keeping clear:
- The plant and the brand are not the same. 'Charlotte's Web' is also a publicly traded hemp-products company (Charlotte's Web Holdings, Inc.). Bottles and tinctures sold on retail shelves under that name are formulated extracts with standardized CBD content, not necessarily flowers of the original cultivar genetics.
- CBD ≠ Charlotte's Web. Many health products marketed alongside the Charlotte's Web story use unrelated hemp biomass and make broad CBD health claims. The clinical evidence for CBD's effects in epilepsy comes from controlled trials of purified CBD pharmaceutical products [3], not from any one cultivar's inherent magic.
- It will not get you high. At ≤0.3% THC, this is a hemp plant in practical and legal terms. People approaching it expecting recreational intoxication report disappointment—which is how the original strain earned its nickname [1].
- The Charlotte Figi story is powerful but limited in scope. That one documented case and the broader movement it inspired catalyzed real policy change. It is not, by itself, clinical evidence that this specific cultivar treats epilepsy. The evidence for CBD in Dravet and Lennox–Gastaut syndromes rests on later randomized trials [3][5].
Charlotte's Web is historically significant. Treat the remainder of the marketing claims with the same skepticism you would apply to any other branded health product.
Frequently asked questions
Is Charlotte's Web an indica or sativa?
Those terms are not reliable predictors of effect or even growing characteristics in modern cannabis; they refer to plant shape and origin myth rather than cannabinoid content Anecdote. Charlotte's Web is classified by its cannabinoid ratio (CBD-dominant, low-THC) and as a hemp cultivar, not by indica/sativa nomenclature. See The Indica/Sativa Myth for more detail.
What is the actual THC content?
Federal regulation requires hemp to contain ≤0.3% THC by dry weight. Charlotte's Web is consistently tested at or below that threshold [1][2]. It does not produce intoxication.
How long does it take to flower?
Approximately 9 weeks indoors under standard 12/12 light. Outdoors in temperate North America, it typically finishes in early to mid-October Weak / limited.
Who actually bred Charlotte's Web?
The Stanley Brothers, Colorado-based growers, developed it in the early 2010s [1]. Full pedigree details are not publicly documented, and the lineage is disputed Disputed. Multiple companies now sell seeds or products labeled 'Charlotte's Web,' but genetic identity is not guaranteed across sources.
Sources
- Reported Young, S. (2013). 'Marijuana stops child's severe seizures.' CNN, August 7, 2013.
- Reported Maa, E. & Figi, P. (2014). 'The case for medical marijuana in epilepsy.' Epilepsia, 55(6), 783–786.
- Peer-reviewed Devinsky, O. et al. (2017). 'Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome.' New England Journal of Medicine, 376(21), 2011–2020.
- Government U.S. Congress (2018). Agriculture Improvement Act of 2018 ('2018 Farm Bill'), Public Law 115-334, Section 10113 (hemp definition and legalization).
- Peer-reviewed Press, C. A., Knupp, K. G., & Chapman, K. E. (2015). 'Parental reporting of response to oral cannabis extracts for treatment of refractory epilepsy.' Epilepsy & Behavior, 45, 49–52.
- Peer-reviewed Sawler, J. et al. (2015). 'The Genetic Structure of Marijuana and Hemp.' PLoS ONE, 10(8), e0133292.
How this page was made
Generation history
Drafted with AI assistance and checked by a separate automated fact-check pass. Not every article has been read by a person. See how articles are made.
Related
- Certificate of Analysis (COA) — Lab-issued document reporting cannabinoid potency and contaminant screening for a specific...
- The Indica/Sativa Myth — The popular classification system contradicts genetics, chemistry, and controlled research...